Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803247 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL3313686 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL1120169 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094498 | 0.89 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094495 | 0.89 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7099012 | 0.84 | DAGLA (0.33) | — | |
| SCHEMBL7099016 | 0.84 | DAGLA (0.33) | — | |
| SCHEMBL7095131 | 0.83 | PRKCA (0.30) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7095130 | 0.83 | PRKCA (0.30) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094794 | 0.79 | CNR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968439-A2 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151200-A2 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2012027331-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2217596-A2 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | Schering Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2158203-A2 | PYRIMIDINEDIONE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2148679-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| EP-2148870-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| EP-2125756-A1 | PHENAZINE COMPOUNDS AND USE THEREOF IN AUTOIMMUNE AND INFLAMMATORY DISEASES | JJ Pharma, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009055331-A2 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008130584-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008089283-A1 | PHENAZINE COMPOUNDS AND USE THEREOF IN AUTOIMMUNE AND INFLAMMATORY DISEASES | JJ PHARMA, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1585520-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | disclosed |